Thursday, 15 October 2026European Markets

Monetary Policy

2 articles

ECB Keeps Dovish Stance as Fed Holds Restrictive Rates, EUR/USD Pressure Mounts

ECB Keeps Dovish Stance as Fed Holds Restrictive Rates, EUR/USD Pressure Mounts

The European Central Bank maintains its gradual rate-cutting path while the Federal Reserve signals prolonged restrictive policy, driving currency divergence. Fed's Jeff Schmid warns further rate cuts risk persistent inflation, contrasting sharply with ECB Vice President Luis de Guindos citing positive inflation news. The policy split widens the 2-year US-German yield spread, threatening capital outflows from European markets.

ViaNews Editorial Team (Europe)•
Federal Reserve signals slower rate cuts in 2026 as labor market stays resilient

Federal Reserve signals slower rate cuts in 2026 as labor market stays resilient

Fed governors Philip Jefferson and Chris Waller indicated the central bank will slow its pace of rate cuts in 2026, citing strong employment data and rates still restricting economic activity. The shift creates diverging prospects for European financial markets tied to dollar movements and transatlantic capital flows.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,377 source documents archived
Query this data → isubstrate.com